Key Points
- Insider Paul Lizzul sold 1,500 shares on Dec. 22 at an average price of $50 for a $75,000 transaction, trimming his holdings by 5.27% to 26,967 shares valued at $1,348,350.
- AnaptysBio beat expectations with $0.52 EPS and $76.32M revenue for the quarter despite negative margins and ROE, and its board authorized a $100 million share repurchase program covering up to 9.6% of outstanding shares.
AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) insider Paul Lizzul sold 1,500 shares of the stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $50.00, for a total transaction of $75,000.00. Following the transaction, the insider directly owned 26,967 shares in the company, valued at $1,348,350. This trade represents a 5.27% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
AnaptysBio Price Performance
Shares of AnaptysBio stock opened at $50.04 on Wednesday. AnaptysBio, Inc. has a one year low of $12.21 and a one year high of $51.43. The firm has a market capitalization of $1.39 billion, a price-to-earnings ratio of -17.74 and a beta of 0.29. The business has a 50-day simple moving average of $39.52 and a 200 day simple moving average of $29.41.
AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $1.58. The business had revenue of $76.32 million for the quarter, compared to analyst estimates of $15.83 million. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 49.94%. On average, sell-side analysts expect that AnaptysBio, Inc. will post -6.08 EPS for the current year.
AnaptysBio declared that its Board of Directors has initiated a share repurchase program on Friday, November 21st that permits the company to repurchase $100.00 million in outstanding shares. This repurchase authorization permits the biotechnology company to purchase up to 9.6% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company's leadership believes its shares are undervalued.
Institutional Investors Weigh In On AnaptysBio
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Larson Financial Group LLC lifted its position in shares of AnaptysBio by 54.6% during the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company's stock worth $41,000 after buying an additional 473 shares in the last quarter. Bessemer Group Inc. increased its position in shares of AnaptysBio by 950.0% during the third quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company's stock valued at $44,000 after acquiring an additional 1,292 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in AnaptysBio by 175.0% during the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company's stock worth $48,000 after acquiring an additional 1,377 shares during the period. Osaic Holdings Inc. boosted its position in AnaptysBio by 11,630.0% in the second quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company's stock worth $52,000 after purchasing an additional 2,326 shares during the last quarter. Finally, Profund Advisors LLC bought a new position in AnaptysBio in the 3rd quarter valued at $201,000.
Wall Street Analyst Weigh In
ANAB has been the topic of several research reports. Stifel Nicolaus lowered their price objective on shares of AnaptysBio from $80.00 to $56.00 and set a "buy" rating on the stock in a report on Thursday, December 11th. HC Wainwright lowered their target price on shares of AnaptysBio from $52.00 to $51.00 and set a "buy" rating on the stock in a report on Monday, November 24th. Truist Financial lifted their price target on AnaptysBio from $20.00 to $36.00 and gave the company a "hold" rating in a research note on Monday, November 10th. Wedbush reissued an "outperform" rating and set a $50.00 price objective on shares of AnaptysBio in a report on Monday, November 24th. Finally, Wells Fargo & Company raised their target price on AnaptysBio from $51.00 to $81.00 and gave the company an "overweight" rating in a report on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $55.40.
View Our Latest Stock Report on AnaptysBio
About AnaptysBio
(
Get Free Report)
AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company's technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.
The company's pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
